Crinetics Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Crinetics Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CRNX

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. 

CEO
Scott R. Struthers
CEOScott R. Struthers
Employees
437
Employees437
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
2008
Founded2008
Employees
437
Employees437

CRNX Key Statistics

Market cap
5.73B
Market cap5.73B
Price-Earnings ratio
-12.45
Price-Earnings ratio-12.45
Dividend yield
Dividend yield
Average volume
2.23M
Average volume2.23M
High today
$56.40
High today$56.40
Low today
$55.28
Low today$55.28
Open price
$56.40
Open price$56.40
Volume
74.79K
Volume74.79K
52 Week high
$57.99
52 Week high$57.99
52 Week low
$24.10
52 Week low$24.10

Stock Snapshot

With a market cap of 5.73B, Crinetics Pharmaceuticals(CRNX) trades at $55.88. The stock has a price-to-earnings ratio of -12.45.

On 2026-01-16, Crinetics Pharmaceuticals(CRNX) stock moved within a range of $55.28 to $56.40. With shares now at $55.88, the stock is trading +1.1% above its intraday low and -0.9% below the session's peak.

Trading volume for Crinetics Pharmaceuticals(CRNX) stock has reached 74.79K, versus its average volume of 2.23M.

Over the past 52 weeks, Crinetics Pharmaceuticals(CRNX) stock has traded between a high of $57.99 and a low of $24.10.

Over the past 52 weeks, Crinetics Pharmaceuticals(CRNX) stock has traded between a high of $57.99 and a low of $24.10.

CRNX News

TipRanks 3d
Crinetics Highlights Breakout Year and Strong Endocrinology Pipeline

Claim 70% Off TipRanks Premium Crinetics Pharmaceuticals ( (CRNX) ) just unveiled an update. On January 13, 2026, Crinetics Pharmaceuticals’ founder and CEO S...

Analyst ratings

94%

of 16 ratings
Buy
93.8%
Hold
6.3%
Sell
0%

People also own

Based on the portfolios of people who own CRNX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .